Eckburg Paul has filed 4 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 30000 shares of AN2 Therapeutics, Inc. ($ANTX) on March 15, 2024.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eckburg Paul | Chief Medical Officer | A | Common Stock | 30000 | $0.00 | 51,416.0000 | 23,600,107 | 140.08% | 0.13% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eckburg Paul | Chief Medical Officer | A | Common | 30000 | $0.00 | 51,416.0000 | 23,600,107 | 140.08% | 0.13% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eckburg Paul | Chief Medical Officer | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 23,600,107 | 9999.99% | 0.25% |
| Feb. 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Eckburg Paul | Chief Medical Officer | A | Stock Option (right to buy) | 70950 | $0.00 | 70,950.0000 | 0 | 9999.99% | 0.00% |